{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:39:05Z","timestamp":1793605145408,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2022-YGJC-68"],"award-info":[{"award-number":["2022-YGJC-68"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2023-BS-105"],"award-info":[{"award-number":["2023-BS-105"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The optimal chemotherapy backbone and specific population of triple-negative breast cancer (TNBC) patients that benefit from neoadjuvant immunotherapy are not well established. This prospective, single-arm, phase II TREND trial assessed the efficacy and safety of tislelizumab plus nab-paclitaxel and epirubicin\/cyclophosphamide-based chemotherapy as a neoadjuvant treatment for TNBC (ChiCTR2000035262). The primary endpoint was pathological complete response (pCR), with the secondary endpoints including safety assessment and objective response rate (ORR). ScRNA-seq, bulk RNA-seq, TCR-seq, cyTOF and WES were performed on pre-treatment and post-treatment samples. Among 53 total enrolled patients, 44 completed the combined neoadjuvant therapy, and 30 of 44 patients (68.18%) achieved pCR. Additionally, 14 out of 44 patients had a complete response (31.82%), with an ORR of 93.18%. The most commonly observed treatment-related adverse events (TRAEs) were alopecia, nausea and liver injury with 6 cases classified as grade 3 or higher adverse events. Immune response-related pathways, including TNF signaling pathway, T cell receptor signaling pathway, were enriched in pCR group. Pre-treatment model was identified and construct to predict response to immunotherapy. CDKN1A+\u2009CD8 T lymphocytes were enriched in pCR group after neoadjuvant immunotherapy. Dynamic change of immune-related pathways at an early stage during the neoadjuvant immunotherapy may be associated with the treatment efficacy. In conclusion, neoadjuvant treatment of tislelizumab with nab-paclitaxel and anthracycline-based chemotherapy showed promising clinical activity and was well-tolerated among TNBC patients, without high incidence of TRAEs. These findings provide evidence supporting neoadjuvant tislelizumab with chemotherapy as an effective rational approach for treating TNBC.<\/jats:p>","DOI":"10.1038\/s41392-025-02254-3","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T19:01:46Z","timestamp":1748199706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin\/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial"],"prefix":"10.1038","volume":"10","author":[{"given":"Qiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingke","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-8512","authenticated-orcid":false,"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9420-1123","authenticated-orcid":false,"given":"Yingying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"2254_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens, L. A. et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann. Oncol. 32, 983\u2013993 (2021).","journal-title":"Ann. Oncol."},{"key":"2254_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N. Engl. J. Med. 387, 217\u2013226 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2254_CR3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2254_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid, P. et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N. Engl. J. Med. 386, 556\u2013567 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2254_CR5","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf, E. A. et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396, 1090\u20131100 (2020).","journal-title":"Lancet"},{"key":"2254_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J. Hematol. Oncol. 15, 121 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2254_CR7","doi-asserted-by":"crossref","unstructured":"Topalian, S. L., Taube, J. M. & Pardoll, D. M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367 (2020).","DOI":"10.1126\/science.aax0182"},{"key":"2254_CR8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","volume":"33","author":"L Gianni","year":"2022","unstructured":"Gianni, L. et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann. Oncol. 33, 534\u2013543 (2022).","journal-title":"Ann. Oncol."},{"key":"2254_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.6004\/jnccn.2022.7016","volume":"20","author":"LM Spring","year":"2022","unstructured":"Spring, L. M., Bar, Y. & Isakoff, S. J. The evolving role of neoadjuvant therapy for operable breast cancer. J. Natl Compr. Canc Netw. 20, 723\u2013734 (2022).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"2254_CR10","first-page":"Cd014805","volume":"9","author":"SR Mason","year":"2023","unstructured":"Mason, S. R. et al. Platinum-based chemotherapy for early triple-negative breast cancer. Cochrane Database Syst. Rev. 9, Cd014805 (2023).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2254_CR11","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","volume":"29","author":"F Poggio","year":"2018","unstructured":"Poggio, F. et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann. Oncol. 29, 1497\u20131508 (2018).","journal-title":"Ann. Oncol."},{"key":"2254_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang, T. et al. The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol. Immunother. 67, 1079\u20131090 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"2254_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 24, 483\u2013495 (2023).","journal-title":"Lancet Oncol."},{"key":"2254_CR14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell 41, 1061\u20131072.e4 (2023).","journal-title":"Cancer Cell"},{"key":"2254_CR15","doi-asserted-by":"crossref","unstructured":"Xu, Y., Zhang, Q., Zhu, B., Wang, M. & Yao, L. Neoadjuvant tislelizumab, a PD-1 mAb plus nab-paclitaxel (nab-P) followed by tislelizumab plus epirubicin\/cyclophosphamide (EC) for triple-negative breast cancers (TNBC): Interim analysis of clinical response in a phase 2 TREND trial. J. Clin. Oncol. 41, e14623-e14623 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.e14623"},{"key":"2254_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ccell.2022.02.013","volume":"40","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Immune phenotypic linkage between colorectal cancer and liver metastasis. Cancer Cell 40, 424\u2013437.e5 (2022).","journal-title":"Cancer Cell"},{"key":"2254_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1146\/annurev-immunol-110519-071134","volume":"39","author":"X Ren","year":"2021","unstructured":"Ren, X. et al. Insights gained from single-cell analysis of immune cells in the tumor microenvironment. Annu Rev. Immunol. 39, 583\u2013609 (2021).","journal-title":"Annu Rev. Immunol."},{"key":"2254_CR18","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578\u20131593.e8 (2021).","journal-title":"Cancer Cell"},{"key":"2254_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","volume":"42","author":"SL Shiao","year":"2024","unstructured":"Shiao, S. L. et al. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell 42, 70\u201384.e8 (2024).","journal-title":"Cancer Cell"},{"key":"2254_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","volume":"27","author":"A Bassez","year":"2021","unstructured":"Bassez, A. et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat. Med 27, 820\u2013832 (2021).","journal-title":"Nat. Med"},{"key":"2254_CR21","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl, S. et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol. 30, 1279\u20131288 (2019).","journal-title":"Ann. Oncol."},{"key":"2254_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med 25, 920\u2013928 (2019).","journal-title":"Nat. Med"},{"key":"2254_CR23","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Dendritic Polymer-Based Nanomedicines Remodel the Tumor Stroma: Improve Drug Penetration and Enhance Antitumor Immune Response. Adv Mater, 36, e2401304 (2024).","DOI":"10.1002\/adma.202401304"},{"key":"2254_CR24","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid, P. et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N. Engl. J. Med 391, 1981\u20131991 (2024).","journal-title":"N. Engl. J. Med"},{"key":"2254_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamaoncol.2022.6901","volume":"9","author":"T Voruganti","year":"2023","unstructured":"Voruganti, T., Soulos, P. R., Mamtani, R., Presley, C. J. & Gross, C. P. Association between age and survival trends in advanced non-small cell lung cancer after adoption of immunotherapy. JAMA Oncol. 9, 334\u2013341 (2023).","journal-title":"JAMA Oncol."},{"key":"2254_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino, P. et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J. Clin. 72, 165\u2013182 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"2254_CR27","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1136\/gutjnl-2018-317479","volume":"68","author":"SH Jiang","year":"2019","unstructured":"Jiang, S. H. et al. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca(2+) signalling in a GABA-independent manner. Gut 68, 1994\u20132006 (2019).","journal-title":"Gut"},{"key":"2254_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108\u2013121 (2022).","journal-title":"Nat. Cancer"},{"key":"2254_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2019.05.041","volume":"178","author":"CH Hsu","year":"2019","unstructured":"Hsu, C. H., Altschuler, S. J. & Wu, L. F. Patterns of early p21 dynamics determine proliferation-senescence cell fate after chemotherapy. Cell 178, 361\u2013373.e12 (2019).","journal-title":"Cell"},{"key":"2254_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1053\/j.gastro.2023.09.017","volume":"166","author":"OM Thoma","year":"2024","unstructured":"Thoma, O. M. et al. p21 prevents the exhaustion of CD4(+) T cells within the antitumor immune response against colorectal cancer. Gastroenterology 166, 284\u2013297.e11 (2024).","journal-title":"Gastroenterology"},{"key":"2254_CR31","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","volume":"54","author":"JM Schenkel","year":"2021","unstructured":"Schenkel, J. M. et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+) CD8(+) T cells in tumor-draining lymph nodes. Immunity 54, 2338\u20132353.e6 (2021).","journal-title":"Immunity"},{"key":"2254_CR32","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","volume":"186","author":"MK Rahim","year":"2023","unstructured":"Rahim, M. K. et al. Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell 186, 1127\u20131143.e18 (2023).","journal-title":"Cell"},{"key":"2254_CR33","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","volume":"185","author":"Q Huang","year":"2022","unstructured":"Huang, Q. et al. The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes. Cell 185, 4049\u20134066.e25 (2022).","journal-title":"Cell"},{"key":"2254_CR34","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med 25, 1251\u20131259 (2019).","journal-title":"Nat. Med"},{"key":"2254_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-21-0515","volume":"10","author":"N Budimir","year":"2022","unstructured":"Budimir, N., Thomas, G. D., Dolina, J. S. & Salek-Ardakani, S. Reversing T-cell exhaustion in cancer: lessons learned from PD-1\/PD-L1 immune checkpoint blockade. Cancer Immunol. Res 10, 146\u2013153 (2022).","journal-title":"Cancer Immunol. Res"},{"key":"2254_CR36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281\u2013291.e9 (2019).","journal-title":"Cell Syst."},{"key":"2254_CR37","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e29 (2021).","journal-title":"Cell"},{"key":"2254_CR38","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"2254_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12688\/f1000research.22139.1","volume":"9","author":"N Borcherding","year":"2020","unstructured":"Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: An R-based toolkit for single-cell immune receptor analysis. F1000Res 9, 47 (2020).","journal-title":"F1000Res"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02254-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02254-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02254-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T19:01:48Z","timestamp":1748199708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02254-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2254"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02254-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}